Evidence map›Paper›PMID 38420129›Full record

Trial reportFrontiers in immunology2024

Innate immune cell activation after HIV-1 vaccine administration is associated with increased antibody production.

Kombo F N'guessan, Kawthar Machmach, Isabella Swafford, Margaret C Costanzo, Lindsay Wieczorek, Dohoon Kim, Siriwat Akapirat, Victoria R Polonis, Punnee Pitisuttithum, Sorachai Nitayaphan and 7 more

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 2 countries.

Kombo F N'guessanUnited States Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States.
Kawthar MachmachUnited States Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States.
Isabella SwaffordUnited States Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States.
Margaret C CostanzoUnited States Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States.
Lindsay WieczorekUnited States Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States.
Dohoon KimUnited States Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States.
Siriwat AkapiratMilitary HIV Research Program (MHRP), Armed Forces Research Institute for Medical Sciences, Bangkok, Thailand.
Victoria R PolonisUnited States Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States.
Punnee PitisuttithumClinical Tropical Medicine, Mahidol University, Bangkok, Thailand.
Sorachai NitayaphanMilitary HIV Research Program (MHRP), Armed Forces Research Institute for Medical Sciences, Bangkok, Thailand.
Sanjay GurunathanSanofi Pasteur, Swiftwater, PA, United States.
Faruk SinangilGlobal Solutions for Infectious Diseases, Lafayette, CA, United States.
Suwat ChariyalertsakResearch Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand.
Julie A AkeUnited States Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States.
Robert J O'connellUnited States Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States.
Sandhya VasanUnited States Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States.
Dominic Paquin-ProulxUnited States Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States.
Walter Reed Army Institute of Research · USHenry M. Jackson Foundation · USArmed Forces Research Institute of Medical Science · THChiang Mai University · THGlobal Solutions for Infectious Diseases · USMahidol University · THSanofi (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The RV144 Thai phase III clinical trial's canarypox-protein HIV vaccine regimen showed modest efficacy in reducing infection. We therefore sought to determine the effects of vaccine administration on innate cell activation and subsequent associations with vaccine-induced immune responses. RV306 was a randomized, double-blind clinical trial in HIV-uninfected Thai adults that tested delayed boosting following the RV144 regimen. PBMC collected from RV306 participants prior to and 3 days after the last boost were used to investigate innate immune cell activation. Our analysis showed an increase in CD38+ mucosal associated invariant T (MAIT) cells, CD38+ invariant natural killer T (iNKT) cells, CD38+ γδ T cells, CD38+, CD69+ and HLA-DR+ NK cells 3 days after vaccine administration. An increase in CD14-CD16+ non-classical monocytes and CD14+CD16+ intermediate monocytes accompanied by a decrease in CD14+CD16- classical monocytes was also associated with vaccine administration. Inclusion of ALVAC-HIV in the boost did not further increase MAIT, iNKT, γδ T, and NK cell activation or increase the proportion of non-classical monocytes. Additionally, NK cell activation 3 days after vaccination was positively associated with antibody titers of HIV Env-specific total IgG and IgG1. Vδ1 T cell activation 3 days after vaccine administration was associated with HIV Env-specific IgG3 titers. Finally, we observed trending associations between MAIT cell activation and Env-specific IgG3 titers and between NK cell activation and TH023 pseudovirus neutralization titers. Our study identifies a potential role for innate cells, specifically NK, MAIT, and γδ T cells, in promoting antibody responses following HIV-1 vaccine administration.

Indexed as

HIV-1HIV InfectionsHIV SeropositivityNatural Killer T-CellsAdultAntibody FormationDouble-Blind MethodHumansImmunity, InnateImmunoglobulin GVaccinationImmunoglobulin Ggamma delta (γδ) T cellsHIV vaccineimmune activationiNKT cellMAIT (mucosal-associated invariant T) cellmonocytesNK cell

Identifiers

PMID38420129
PMCPMC10900843
OpenAlexW4391784444

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.